{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:17Z","timestamp":1793155817499,"version":"4.5.0"},"reference-count":21,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PTT"],"DOI":"10.2147\/ptt.s544166","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:45:10Z","timestamp":1754390710000},"page":"351-360","source":"Crossref","is-referenced-by-count":3,"title":["Bimekizumab: The First FDA-Approved Dual IL-17A\/IL-17F Inhibitor for Plaque Psoriasis \u2013 A Comprehensive Literature Review"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Sukainah","family":"Al Alshaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Almarhoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Momattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Aleid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Almousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alqaisum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Mobarki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Almakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Alturfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouther","family":"Almajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e12946","DOI":"10.1111\/sji.12946","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2119767","DOI":"10.1080\/21645515.2022.2119767","volume":"18","author":"Koppu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2023.2125380","volume":"19","author":"Tanaka","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2147\/PPA.S350760","volume":"17","author":"Cami\u00f1a-Conforto","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/PTT.S179283","volume":"9","author":"Chiricozzi","year":"2019","journal-title":"Psoriasis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.4049\/jimmunol.0902464","volume":"184","author":"Guilloteau","year":"2010","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"A13.1","DOI":"10.1136\/annrheumdis-2017-eular.4966","volume":"76","author":"Maroof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref15","unstructured":"National Institute for Health and Care Excellence (NICE). Bimekizumab for treating moderate to severe plaque psoriasis. NICE Guideline TA723. Available from: https:\/\/www.nice.org.uk\/guidance\/ta723. Accessed August 1, 2025."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.2147\/PPA.S117006","volume":"10","author":"Belinchon","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref21","first-page":"CD011535","volume":"2023","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Psoriasis: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/105484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/105484","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:45:11Z","timestamp":1754390711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/bimekizumab-the-first-fda-approved-dual-il-17ail-17f-inhibitor-for-pla-peer-reviewed-fulltext-article-PTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2147\/ptt.s544166","relation":{},"ISSN":["2230-326X"],"issn-type":[{"value":"2230-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}